G
Gordon H. Guyatt
Researcher at McMaster University
Publications - 1749
Citations - 262329
Gordon H. Guyatt is an academic researcher from McMaster University. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 231, co-authored 1620 publications receiving 228631 citations. Previous affiliations of Gordon H. Guyatt include Memorial Sloan Kettering Cancer Center & Cayetano Heredia University.
Papers
More filters
Journal ArticleDOI
Guidelines for the clinical and economic evaluation of health care technologies
Gordon H. Guyatt,Michael Drummond,David Feeny,David Feeny,Peter Tugwell,Greg L. Stoddart,Greg L. Stoddart,Haynes Rb,Kathryn Bennett,R Labelle +9 more
TL;DR: It is argued that decision making can be improved by striving towards a more rational approach to the adoption and utilization of health technology and a comprehensive set of guidelines for both clinical and economic evaluation is proposed.
Journal ArticleDOI
Measuring functional status in chronic lung disease: conclusions from a randomized control trial
TL;DR: The Chronic Respiratory Questionnaire (CRQ) was more powerful than the other questionnaires, either the Oxygen Cost Diagram or the Medical Research Council Dyspnea Questionnaire as modified by the Rand Corporation, and showed a higher correlation with changes in spirometry, walk test score, dyspnea following the walk test, and global ratings of dysPnea than did the other two measures.
Journal ArticleDOI
Users' Guides to the Medical Literature: XV. How to Use an Article About Disease Probability for Differential Diagnosis
TL;DR: An experienced clinician working at a hospital emergency department asks the question: “In patients presenting with palpitations, what is the frequency of underlying disorders?”
Journal ArticleDOI
High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission.
Arnav Agarwal,John Basmaji,Fiona Muttalib,David Granton,Dipayan Chaudhuri,Devin Chetan,Malini Hu,Shannon M. Fernando,Kimia Honarmand,Layla Bakaa,Sonia Brar,Bram Rochwerg,Neill K. J. Adhikari,Neill K. J. Adhikari,Francois Lamontagne,Srinivas Murthy,David S.C. Hui,Charles D. Gomersall,Samira Mubareka,Samira Mubareka,Janet V. Diaz,Karen E. A. Burns,Karen E. A. Burns,Rachel Couban,Quazi Ibrahim,Gordon H. Guyatt,Per Olav Vandvik +26 more
TL;DR: High-flow nasal cannula may reduce the need for invasive ventilation and escalation of therapy compared with COT in COVID-19 patients with acute hypoxemic respiratory failure, and this benefit must be balanced against the unknown risk of airborne transmission.